drugset
Drugs / CCR2/CCR5 dual antagonist
last change Feb 2025 re-read 3 minutes ago

CCR2/CCR5 dual antagonist

targets CCR2, CCR5 via inhibition

Developed for
pancreatic ductal adenocarcinoma
Investigated by
Bristol-Myers Squibb · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Trials 1

today NCT03767582 · Ph 1/2
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03767582 Dec 2019 → Feb 2025 pancreatic ductal adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CCR2/CCR5 dual antagonist ClinicalTrials.gov intervention name — accepted as the source's own label NCT03767582 ↗
Action Inhibit “CCR2/CCR5 dual antagonist” NCT03767582 ↗
Route Oral “administered orally twice a day” NCT03767582 ↗
Target CCR2 “CCR2/CCR5 dual antagonist” NCT03767582 ↗
Target CCR5 “CCR2/CCR5 dual antagonist” NCT03767582 ↗